Chief Executive Officer
A
Apaxen
The startup develops anti-inflammatory therapeutics that target NLRP3 inflammasome activation by creating first-in-class small molecules that inhibit the interaction between macrophage migration inhibitory factor and NLRP3. This approach aims to provide effective treatments for diseases characterized by chronic NLRP3 inflammasome activation.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$4.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops anti-inflammatory therapeutics that target NLRP3 inflammasome activation by creating first-in-class small molecules that inhibit the interaction between macrophage migration inhibitory factor and NLRP3. This approach aims to provide effective treatments for diseases characterized by chronic NLRP3 inflammasome activation.